Sanofi

News

Sanofi wagers $400m on miRecule muscular dystrophy therapy

Sanofi has added to its rare disease pipeline by licensing an antibody-RNA conjugate (ARC) for facioscapulohumeral muscular dystrophy (FSHD), a genetic muscle disorder, from US biotech miRe

News

FDA clears Dupixent as first drug for rare skin disorder

Sanofi and Regeneron have claimed the first approval in the US for a drug for prurigo nodularis, after the FDA gave a green light to Dupixent as a treatment for adults with the rare skin di

News

West Chester - Circa November 2020: AstraZeneca plant. AstraZeneca has been working on a vaccine for the Coronavirus, COVID and COVID-19.

AZ and Ionis' PCSK9 cholesterol drug will not move to phase ...

AstraZeneca has taken the decision not to move a PCSK9-targeting antisense drug licensed from Ionis into a phase 3 programme, removing a competitor to Novartis' rival therapy Leqvio.

News

Sanofi invests in French vaccines facility

Firm to invest 170 million euros in vaccines manufacturing facility in France

News

Many women unaware of epilepsy drug safety warning - survey

Nearly seven out of ten women surveyed about an epilepsy drug have not received new safety warnings, according to a new survey.

News

CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevent...

Sanofi and AstraZeneca are closing in on EU approval of nirsevimab, their long-acting antibody for the protection of newborns and infants from respiratory syncytial virus (RSV) infections.<

Sanofi wagers $400m on miRecule muscular dystrophy therapy

FDA clears Dupixent as first drug for rare skin disorder

AZ and Ionis' PCSK9 cholesterol drug will not move to phase ...

Sanofi invests in French vaccines facility

Many women unaware of epilepsy drug safety warning - survey

CHMP says yes to Sanofi/AstraZeneca antibody for RSV prevent...

Delivering the right behavioural ingredients for the moment,...

How to meet your physicians where they are online

Sanofi

Editor's Picks